Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Shocking clots away: muscle zaps may prevent dangerous blood clots in hospital patients

NCT ID NCT06135857

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether using a device that electrically stimulates arm muscles can prevent blood clots caused by PICC catheters in critically ill patients. 120 adults in intensive care units were randomly assigned to receive either standard care or standard care plus two daily 20-minute sessions of muscle stimulation. Researchers used ultrasound to check for clots over the first few weeks after catheter placement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
electromuscular stimulation device
What this could lead to
If it works, this could offer a simple, non-drug way to prevent dangerous blood clots in hospitalized patients with PICC lines.
What could go wrong
This is a small, early-stage trial (120 patients) testing a device, so results may not apply broadly. The therapy requires daily sessions and may not be practical for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Dec 2023

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients admitted to the critical unit with a PICC whose insertion is done by the EIAV of the same hospital. * Patients between 18 and 80 years of age. * Treatments related to the device protocolized by the same hospital as the EIAV implanter. Exclusion Criteria: * Patients who do not sign informed consent. * Patients with pacemakers and/or implantable automatic defibrillators. * Patients with epilepsy. * Removal of the device within the first 15 days after insertion. * Hospital discharge, transfer to another hospital or death lethalis during the duration of the study. * Displacement of the tip of the catheter outside the lower ⅓ of the superior vein cava during the study period. * Presence of lesions in the place where the electrodes must be placed to perform the electrostimulation therapy. * Non-compliance with catheter monitoring: Of the five ultrasound controls protocolized in the study, 80% were not complied with.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thrombosis; catheter, infusion catheter (vascular) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Dr. Josep Trueta de Girona

    Girona, Espanya, 17007, Spain